FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2338029409> ?p ?o ?g. }

• W2338029409 abstract "In 2014, an estimated 46,420 people will be diagnosed with pancreatic cancer in the United States, and approximately 39,590 will die from the disease. Gemcitabine has been established as the first-line treatment for advanced pancreatic cancer. However, this type of cancer has responded poorly to many therapeutic agents including gemcitabine, mainly due to inadequate drug accumulation at the desired tumor location and drug resistance. Liposomes represent a convenient method to deliver drugs to solid tumors. The drug carrier enhances the accumulation of the drug at the tumor site and has been shown to overcome drug resistance. Liposomes can direct the drug away from normal tissue and minimize unwanted drug side effects. However, more selective tumor targeting of cytotoxic drug-loaded liposomes to pancreatic tumors will further improve efficacy and will likely reduce toxicity. The present study investigated whether the inclusion of extracted lipids derived from pancreatic cancer cells would improve the selective uptake of liposomes by pancreatic cancer cells and formulation effects. We hypothesized that the inclusion of cell membrane lipid-extracted materials in the preparation of nanoliposomes will promote selective cellular uptake and improved cytotoxic drug effects. To test the hypothesis, two different pancreatic cancer cell lines were employed for the study (PANC-1 and Capan-2), and hTERT (a human immortalized normal pancreatic duct cell line) used as a healthy cell control. The human prostate (LNCap) and colorectal cancer (COLO-205) cell lines were used as negative controls. Various nanoliposome preparations were prepared and evaluated in terms of particle size, zeta potential and relative affinity of CLENs for target cells and fluorescence microscopy. The particle size of these nanoliposomes ranged between 92-176 nm and the zeta potential was negatively-charged (-14.07 and -34.95 mV). The Sulforhodamine B cell viability assay showed that CLENs was non-toxic to cells over the full concentration range evaluated when compared to conventional liposomes. The cellular uptake of the five different nanoliposome preparations was highest for the cell line from which the lipid material used to prepare CLENs was extracted (P 0.05). Fluorescence microscopic analyses supported the cellular uptake studies. The incorporation of gemcitabine in CLENs may represent a promising approach for the treatment of pancreatic cancer. Cytotoxic drug studies with gemcitabine are currently underway. Citation Format: Taha Y. Alqahtani, Robert Campbell. Development and evaluation of cell membrane lipid-extracted nanoliposomes (CLENs) for the treatment of cancer using cellular models of human pancreatic cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5528. doi:10.1158/1538-7445.AM2015-5528" @default.
• W2338029409 created "2016-06-24" @default.
• W2338029409 creator A5010537348 @default.
• W2338029409 creator A5085010424 @default.
• W2338029409 date "2015-08-01" @default.
• W2338029409 modified "2023-09-26" @default.
• W2338029409 title "Abstract 5528: Development and evaluation of cell membrane lipid-extracted nanoliposomes (CLENs) for the treatment of cancer using cellular models of human pancreatic cancer" @default.
• W2338029409 doi "https://doi.org/10.1158/1538-7445.am2015-5528" @default.
• W2338029409 hasPublicationYear "2015" @default.
• W2338029409 type Work @default.
• W2338029409 sameAs 2338029409 @default.
• W2338029409 citedByCount "0" @default.
• W2338029409 crossrefType "proceedings-article" @default.
• W2338029409 hasAuthorship W2338029409A5010537348 @default.
• W2338029409 hasAuthorship W2338029409A5085010424 @default.
• W2338029409 hasConcept C121608353 @default.
• W2338029409 hasConcept C126322002 @default.
• W2338029409 hasConcept C154317977 @default.
• W2338029409 hasConcept C185154212 @default.
• W2338029409 hasConcept C185592680 @default.
• W2338029409 hasConcept C202751555 @default.
• W2338029409 hasConcept C2779723316 @default.
• W2338029409 hasConcept C2780035454 @default.
• W2338029409 hasConcept C2780192828 @default.
• W2338029409 hasConcept C2780210213 @default.
• W2338029409 hasConcept C2780258809 @default.
• W2338029409 hasConcept C502942594 @default.
• W2338029409 hasConcept C55493867 @default.
• W2338029409 hasConcept C71924100 @default.
• W2338029409 hasConcept C96232424 @default.
• W2338029409 hasConcept C98274493 @default.
• W2338029409 hasConceptScore W2338029409C121608353 @default.
• W2338029409 hasConceptScore W2338029409C126322002 @default.
• W2338029409 hasConceptScore W2338029409C154317977 @default.
• W2338029409 hasConceptScore W2338029409C185154212 @default.
• W2338029409 hasConceptScore W2338029409C185592680 @default.
• W2338029409 hasConceptScore W2338029409C202751555 @default.
• W2338029409 hasConceptScore W2338029409C2779723316 @default.
• W2338029409 hasConceptScore W2338029409C2780035454 @default.
• W2338029409 hasConceptScore W2338029409C2780192828 @default.
• W2338029409 hasConceptScore W2338029409C2780210213 @default.
• W2338029409 hasConceptScore W2338029409C2780258809 @default.
• W2338029409 hasConceptScore W2338029409C502942594 @default.
• W2338029409 hasConceptScore W2338029409C55493867 @default.
• W2338029409 hasConceptScore W2338029409C71924100 @default.
• W2338029409 hasConceptScore W2338029409C96232424 @default.
• W2338029409 hasConceptScore W2338029409C98274493 @default.
• W2338029409 hasLocation W23380294091 @default.
• W2338029409 hasOpenAccess W2338029409 @default.
• W2338029409 hasPrimaryLocation W23380294091 @default.
• W2338029409 hasRelatedWork W1735395619 @default.
• W2338029409 hasRelatedWork W1766528071 @default.
• W2338029409 hasRelatedWork W1970507280 @default.
• W2338029409 hasRelatedWork W2017574717 @default.
• W2338029409 hasRelatedWork W2021651355 @default.
• W2338029409 hasRelatedWork W2257520068 @default.
• W2338029409 hasRelatedWork W2294999722 @default.
• W2338029409 hasRelatedWork W2299956717 @default.
• W2338029409 hasRelatedWork W2330898379 @default.
• W2338029409 hasRelatedWork W2523143984 @default.
• W2338029409 hasRelatedWork W2562299100 @default.
• W2338029409 hasRelatedWork W2734590026 @default.
• W2338029409 hasRelatedWork W2758161363 @default.
• W2338029409 hasRelatedWork W2859146093 @default.
• W2338029409 hasRelatedWork W2883932161 @default.
• W2338029409 hasRelatedWork W2885037386 @default.
• W2338029409 hasRelatedWork W2886151276 @default.
• W2338029409 hasRelatedWork W2953452881 @default.
• W2338029409 hasRelatedWork W2955367567 @default.
• W2338029409 hasRelatedWork W3097694590 @default.
• W2338029409 isParatext "false" @default.
• W2338029409 isRetracted "false" @default.
• W2338029409 magId "2338029409" @default.
• W2338029409 workType "article" @default.